Research
Hormonal
GLP-1 receptor agonists (Exenatide and Liraglutide) are marketed drugs that suppress appetite and reduce body weight while improving glycemic control in diabetic patients.
If you have Type 2 Diabetes, ask your doctor about GLP-1 receptor agonists like Exenatide or Liraglutide. These are already available medications that help control blood sugar and also help with weight loss by suppressing appetite.
GoodSupportsHIGH confidence
Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight.
Why this rating
Cited as 'already been marketed' with demonstrated effects in the review.
Source
Anti-obesity drugs: a review about their effects and their safety
Giuseppe Derosa et al. · Expert Opinion on Drug Safety · 2012
DOI 10.1517/14740338.2012.675326
narrative_reviewCited 184×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sibutramine and Rimonabant, previously approved anti-obesity drugs, were withdrawn from the market due to serious adverse effects, specifically increased cardiovascular risk and psychiatric disorders, respectively.Strong
- Orlistat is the only currently available long-term pharmacological treatment for obesity in Europe because it offers a favorable safety profile regarding cardiovascular events and diabetic control, despite being less effective for weight reduction than withdrawn agents.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →